Effect of goldthioglucose on long-term cultures of mouse hypothalamus.

H. M. Geller,R. Cechner,D. Fleming

Neurobiology

Abstract:

What problem does this paper attempt to address?

Genetically engineered T cells for cancer immunotherapy

Dan Li,Xue Li,Wei-Lin Zhou,Yong Huang,Xiao Liang,Lin Jiang,Xiao Yang,Jie Sun,Zonghai Li,Wei-Dong Han,Wei Wang

DOI: https://doi.org/10.1038/s41392-019-0070-9

IF: 39.3

2019-01-01

Signal Transduction and Targeted Therapy

Abstract:T cells in the immune system protect the human body from infection by pathogens and clear mutant cells through specific recognition by T cell receptors (TCRs). Cancer immunotherapy, by relying on this basic recognition method, boosts the antitumor efficacy of T cells by unleashing the inhibition of immune checkpoints and expands adaptive immunity by facilitating the adoptive transfer of genetically engineered T cells. T cells genetically equipped with chimeric antigen receptors (CARs) or TCRs have shown remarkable effectiveness in treating some hematological malignancies, although the efficacy of engineered T cells in treating solid tumors is far from satisfactory. In this review, we summarize the development of genetically engineered T cells, outline the most recent studies investigating genetically engineered T cells for cancer immunotherapy, and discuss strategies for improving the performance of these T cells in fighting cancers.
CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Ping Ren,Chuyue Zhang,Wenping Li,Xian Wang,Aibing Liang,Guang Yang,Hongtao Xu,Peixiang Ma

DOI: https://doi.org/10.1002/adbi.202101262

2022-01-01

Advanced Biology

Abstract:Chimeric antigen receptors (CAR) redirect T cells to specifically recognize and eliminate tumor cells. CAR-T therapy has achieved successful clinical outcomes, and it has been transformed into commercially available products to treat acute lymphoblastic leukemia and B cell lymphoma. These breakthroughs have motivated hundreds of CAR-T clinical trials initiated each year, with ≈900 cases registered on the ClinicalTrials website till 2021. Accumulating clinical experiences have highlighted some limitations of this strategy, e.g., relapse after complete response, poor efficacy in solid tumors, on-target off-tumor toxicities, lack of persistence, and tumor resistance. These challenges limit the therapeutic application of CAR-T cells. Multidisciplinary approaches are actively investigated to address these issues. In this review, the antigens, CAR designs, and cell sources are summarized in clinical trials from 2020 to 2021. The innovative modular and programmable designs in CAR-T cells, including advances in signaling domains, antigen-recognition domains, T cell engineering, and cell resources, are further discussed. Integrative genetic and chemical engineering strategies are promising to improve the versatility, antitumor efficacy, persistence, and safety of CAR-T cells. In the future, the next generation of CAR-T cell therapies will offer more options for patients who are refractory to standard tumor therapies.
Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Zhibo Zheng,Siyuan Li,Mohan Liu,Chuyan Chen,Lu Zhang,Daobin Zhou,Zheng,Li,Liu,Chen,Zhang,Zhou

DOI: https://doi.org/10.3390/cancers15133476

2023-07-03

Cancers

Abstract:Chimeric antigen receptor (CAR)-T cell therapy is a promising form of immunotherapy that has seen significant advancements in the past few decades. It involves genetically modifying T cells to target cancer cells expressing specific antigens, providing a novel approach to treating various types of cancer. However, the initial success of first-generation CAR-T cells was limited due to inadequate proliferation and undesirable outcomes. Nonetheless, significant progress has been made in CAR-T cell engineering, leading to the development of the latest fifth-generation CAR-T cells that can target multiple antigens and overcome individual limitations. Despite these advancements, some shortcomings prevent the widespread use of CAR-T therapy, including life-threatening toxicities, T-cell exhaustion, and inadequate infiltration for solid tumors. Researchers have made considerable efforts to address these issues by developing new strategies for improving CAR-T cell function and reducing toxicities. This review provides an overview of the path of CAR-T cell development and highlights some of the prominent advances in its structure and manufacturing process, which include the strategies to improve antigen recognition, enhance T-cell activation and persistence, and overcome immune escape. Finally, the review briefly covers other immune cells for cancer therapy and ends with the discussion on the broad prospects of CAR-T in the treatment of various diseases, not just hematological tumors, and the challenges that need to be addressed for the widespread clinical application of CAR-T cell therapies.

oncology
Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance

Nils Wellhausen,Joanne Baek,Saar I. Gill,Carl H. June

DOI: https://doi.org/10.1038/s41568-024-00723-5

IF: 78.5

2024-07-25

Nature Reviews Cancer

Abstract:Adoptive cell therapies engineered to express chimeric antigen receptors (CARs) or transgenic T cell receptors (TCRs) to recognize and eliminate cancer cells have emerged as a promising approach for achieving long-term remissions in patients with cancer. To be effective, the engineered cells must persist at therapeutically relevant levels while avoiding off-tumour toxicities, which has been challenging to realize outside of B cell and plasma cell malignancies. This Review discusses concepts to enhance the efficacy, safety and accessibility of cellular immunotherapies by endowing cells with selective resistance to small-molecule drugs or antibody-based therapies to facilitate combination therapies with substances that would otherwise interfere with the functionality of the effector cells. We further explore the utility of engineering healthy haematopoietic stem cells to confer resistance to antigen-directed immunotherapies and small-molecule targeted therapies to expand the therapeutic index of said targeted anticancer agents as well as to facilitate in vivo selection of gene-edited haematopoietic stem cells for non-malignant applications. Lastly, we discuss approaches to evade immune rejection, which may be required in the setting of allogeneic cell therapies. Increasing confidence in the tools and outcomes of genetically modified cell therapy now paves the way for rational combinations that will open new therapeutic horizons.

oncology
Engineering strategies to safely drive CAR T-cells into the future

Matteo Rossi,Eytan Breman

DOI: https://doi.org/10.3389/fimmu.2024.1411393

IF: 7.3

2024-06-20

Frontiers in Immunology

Abstract:Chimeric antigen receptor (CAR) T-cell therapy has proven a breakthrough in cancer treatment in the last decade, giving unprecedented results against hematological malignancies. All approved CAR T-cell products, as well as many being assessed in clinical trials, are generated using viral vectors to deploy the exogenous genetic material into T-cells. Viral vectors have a long-standing clinical history in gene delivery, and thus underwent iterations of optimization to improve their efficiency and safety. Nonetheless, their capacity to integrate semi-randomly into the host genome makes them potentially oncogenic via insertional mutagenesis and dysregulation of key cellular genes. Secondary cancers following CAR T-cell administration appear to be a rare adverse event. However several cases documented in the last few years put the spotlight on this issue, which might have been underestimated so far, given the relatively recent deployment of CAR T-cell therapies. Furthermore, the initial successes obtained in hematological malignancies have not yet been replicated in solid tumors. It is now clear that further enhancements are needed to allow CAR T-cells to increase long-term persistence, overcome exhaustion and cope with the immunosuppressive tumor microenvironment. To this aim, a variety of genomic engineering strategies are under evaluation, most relying on CRISPR/Cas9 or other gene editing technologies. These approaches are liable to introduce unintended, irreversible genomic alterations in the product cells. In the first part of this review, we will discuss the viral and non-viral approaches used for the generation of CAR T-cells, whereas in the second part we will focus on gene editing and non-gene editing T-cell engineering, with particular regard to advantages, limitations, and safety. Finally, we will critically analyze the different gene deployment and genomic engineering combinations, delineating strategies with a superior safety profile for the production of next-generation CAR T-cell.

immunology
Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

Dongdong Ti,Yunfei Niu,Zhiqiang Wu,Xiaobing Fu,Weidong Han

DOI: https://doi.org/10.1007/s11427-018-9411-4

2018-11-01

Science China Life Sciences

Abstract:The host immune system plays an instrumental role in the surveillance and elimination of tumors by recognizing and destroying cancer cells. In recent decades, studies have mainly focused on adoptive immunotherapy using engineered T cells for the treatment of malignant diseases. Through gene engraftment of the patient’s own T cells with chimeric antigen receptor (CAR), they can recognize tumor specific antigens effectively and eradicate selectively targeted cells in an MHC-independent fashion. To date, CAR-T cell therapy has shown great clinical utility in patients with B-cell leukemias. Owing to different CAR designs and tumor complex microenvironments, genetically redirected T cells may generate diverse biological properties and thereby impact their long-term clinical performance and outcome. Meanwhile some unexpected toxicities that result from CAR-T cell application have been examined and limited the curative effects. Diverse important parameters are closely related with adoptively transferred cell behaviors, including CAR-T cells homing, CAR constitutive signaling, T cell differentiation and exhaustion. Thus, understanding CARs molecular design to improve infused cell efficacy and safety is crucial to clinicians and patients who are considering this novel cancer therapeutics. In this review, the developments in CAR-T cell therapy and the limitations and perspectives in optimizing this technology towards clinical application are discussed.

biology
Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy

Yuning Chen,Yichen Zhu,Adam Kramer,Ying Fang,Matthew Wilson,Yan-Ruide Li,Lili Yang

DOI: https://doi.org/10.3389/fmed.2023.1135468

IF: 3.9

2023-03-29

Frontiers in Medicine

Abstract:The realm of cell-based immunotherapy holds untapped potential for the development of next-generation cancer treatment through genetic engineering of chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapies for targeted eradication of cancerous malignancies. Such allogeneic “off-the-shelf” cell products can be advantageously manufactured in large quantities, stored for extended periods, and easily distributed to treat an exponential number of cancer patients. At current, patient risk of graft-versus-host disease (GvHD) and host-versus-graft (HvG) allorejection severely restrict the development of allogeneic CAR-T cell products. To address these limitations, a variety of genetic engineering strategies have been implemented to enhance antitumor efficacy, reduce GvHD and HvG onset, and improve the overall safety profile of T-cell based immunotherapies. In this review, we summarize these genetic engineering strategies and discuss the challenges and prospects these approaches provide to expedite progression of translational and clinical studies for adoption of a universal cell-based cancer immunotherapy.

medicine, general & internal
Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility

Lorenzo Giorgioni,Alessandra Ambrosone,Maria Francesca Cometa,Anna Laura Salvati,Robert Nisticò,Armando Magrelli

DOI: https://doi.org/10.3390/ijms251910365

IF: 5.6

2024-09-27

International Journal of Molecular Sciences

Abstract:Chimeric antigen receptor (CAR) T-cell therapy has achieved notable success in treating hematological cancers but faces significant challenges in solid-tumor treatment and overall efficacy. Key limitations include T-cell exhaustion, tumor relapse, immunosuppressive tumor microenvironments (TME), immunogenicity, and antigen heterogeneity. To address these issues, various genetic engineering strategies have been proposed. Approaches such as overexpression of transcription factors or metabolic armoring and dynamic CAR regulation are being explored to improve CAR T-cell function and safety. Other efforts to improve CAR T-cell efficacy in solid tumors include targeting novel antigens or developing alternative strategies to address antigen diversity. Despite the promising preclinical results of these solutions, challenges remain in translating CAR T-cell therapies to the clinic to enable economically viable access to these transformative medicines. The efficiency and scalability of autologous CAR T-cell therapy production are hindered by traditional, manual processes which are costly, time-consuming, and prone to variability and contamination. These high-cost, time-intensive processes have complex quality-control requirements. Recent advancements suggest that smaller, decentralized solutions such as microbioreactors and automated point-of-care systems could improve production efficiency, reduce costs, and shorten manufacturing timelines, especially when coupled with innovative manufacturing methods such as transposons and lipid nanoparticles. Future advancements may include harmonized consumables and AI-enabled technologies, which promise to streamline manufacturing, reduce costs, and enhance production quality.

biochemistry & molecular biology,chemistry, multidisciplinary
Advanced strategies in improving the immunotherapeutic effect of CAR‐T cell therapy

Minmin Wang,Linzi Jia,Xiangpeng Dai,Xiaoling Zhang

DOI: https://doi.org/10.1002/1878-0261.13621

2024-03-10

Molecular Oncology

Abstract:The review summarizes and discusses recently developed or optimized strategies including the delivery of CAR gene, drug administration regimen, the CAR with molecular switch or logic gate control, allogeneic and super CAR‐T, double targets CAR‐T, CAR‐T targets for exploration, utilization of nano‐antibody/nanomaterials and gene‐editing, combination with radiotherapy, chemotherapy and vaccine, to improve the therapeutic effects of CAR‐T cells therapies. Chimeric antigen receptor (CAR‐T) cell therapy is a newly developed immunotherapy strategy and has achieved satisfactory outcomes in the treatment of hematological malignancies. However, some adverse effects related to CAR‐T cell therapy have to be resolved before it is widely used in clinics as a cancer treatment. Furthermore, the application of CAR‐T cell therapy in the treatment of solid tumors has been hampered by numerous limitations. Therefore, it is essential to explore novel strategies to improve the therapeutic effect of CAR‐T cell therapy. In this review, we summarized the recently developed strategies aimed at optimizing the generation of CAR‐T cells and improving the anti‐tumor efficiency of CAR‐T cell therapy. Furthermore, the discovery of new targets for CAR‐T cell therapy and the combined treatment strategies of CAR‐T cell therapy with chemotherapy, radiotherapy, cancer vaccines and nanomaterials are highlighted.

oncology
CAR T cells: Building on the CD19 paradigm

Anat Globerson Levin,Isabelle Rivière,Zelig Eshhar,Michel Sadelain

DOI: https://doi.org/10.1002/eji.202049064

2021-08-02

European Journal of Immunology

Abstract:<p>Spearheaded by the therapeutic use of chimeric antigen receptors (CARs) targeting CD19, synthetic immunology has entered the clinical arena. CARs are recombinant receptors for antigen that engage cell surface molecules through the variable region of an antibody and signal through arrayed T cell activating and costimulatory domains. CARs allow redirection of T cell cytotoxicity against any antigen of choice, independent of MHC expression. Patient T cells engineered to express CARs specific for CD19 have yielded remarkable outcomes in subjects with relapsed/refractory B cell malignancies, setting off unprecedented interest in T cell engineering and cell-based cancer immunotherapy. In this review, we present the challenges to extend the use of CAR T cells to solid tumors and other pathologies. We further highlight progress in CAR design, cell manufacturing and genome editing, which in aggregate hold the promise of generating safer and more effective genetically instructed immunity. Novel engineered cell types, including innate T cell types, natural killer (NK) cells, macrophages and induced pluripotent stem (iPS) cell-derived immune cells, are on the horizon, as are applications of CAR T cells to treat autoimmunity, severe infections and senescence-associated pathologies.</p><p>This article is protected by copyright. All rights reserved</p>

immunology
Laboratory Studies of IS Failure as Escalating Commitment to a Failing Course of Action: Overcoming the Obstacles

M. Keil,R. Mixon

Abstract:Runaway information technology (IT) projects - projects lhat exhibit significant overruns in project schedule and/or budget - represent a type of IT failure that can cost firms millions of dollars. While such projects have been frequently reported in the press (Betts 1992; Kindel 1992; Rothfeder 1988), this phenomenon has received relatively little attention from information systems researchers. Even though most runaway IT projects are eventually tenninated (or significantly scaled down in order to bring them under control), there are anecdotal data suggesting that managers allow thesc projects to c on t i nue f o r t oo l ong be f o r e t a k i ng c o rr e c t i v e a c li on . Many runaway IT projects appear to represent what can be described as escalating commiunent to a failing course of action (Brockner 1992) and we believe that a large number of IT failures can be described in such terms. Escalating commitment to a failing course of action occurs when a decision maker, who receives significant negative feedback concerning a project, continues to allocate resources to the project when a rational decision maker would make the choice to abandon (Brockner 1992 ; S t a w and R o ss 1987 ) . Several theories have been offered to explain this phenomenon including self-justification theory and the so-called sunk cost effect which can be explained by prospect theory. In order to gain a better understanding of runaway IT projects, we have developed a broad-based research program that includes both field-based and laboratory-based studies that are grounded in escalation theory. Here, we focus on the results of a series of controlled experiments that have been conducted to test whether escalation can be observed within an IT context and to learn more about the factors that may promote or impede this phenomenon. Preliminary results indicate that both the level of sunk cost and
CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments

Manasi P Jogalekar,Ramya Lakshmi Rajendran,Fatima Khan,Crismita Dmello,Prakash Gangadaran,Byeong-Cheol Ahn

DOI: https://doi.org/10.3389/fimmu.2022.925985

2022-07-22

Abstract:Chimeric antigen receptor (CAR)-T cell therapy is a progressive new pillar in immune cell therapy for cancer. It has yielded remarkable clinical responses in patients with B-cell leukemia or lymphoma. Unfortunately, many challenges remain to be addressed to overcome its ineffectiveness in the treatment of other hematological and solidtumor malignancies. The major hurdles of CAR T-cell therapy are the associated severe life-threatening toxicities such as cytokine release syndrome and limited anti-tumor efficacy. In this review, we briefly discuss cancer immunotherapy and the genetic engineering of T cells and, In detail, the current innovations in CAR T-cell strategies to improve efficacy in treating solid tumors and hematologic malignancies. Furthermore, we also discuss the current challenges in CAR T-cell therapy and new CAR T-cell-derived nanovesicle therapy. Finally, strategies to overcome the current clinical challenges associated with CAR T-cell therapy are included as well.
CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers

Virgínia Picanço-Castro,Kamilla Swiech,Kelen Cristina Ribeiro Malmegrim,Dimas Tadeu Covas

DOI: https://doi.org/10.1007/978-1-0716-0146-4_1

Abstract:Immunotherapy has been growing in the past decade as a therapeutic alternative for cancer treatment. In this chapter, we deal with CAR-T cells, genetically engineered autologous T cells to express a chimeric receptor specific for an antigen expressed on tumor cell surface. While this type of personalized therapy is revolutionizing cancer treatment, especially B cell malignancies, it has some challenging limitations. Here, we discuss the basic immunological and technological aspects of CAR-T cell therapy, the limitations that have compromised its efficacy and safety, and the current proposed strategies to overcome these limitations, thereby allowing for greater therapeutic application of CAR-T cells.
Radial Velocities Within the Great Nebula of Orion.

E. B. Frost

DOI: https://doi.org/10.1073/PNAS.1.7.416

1915-07-01

Abstract:The Astrophysical Journal for October, 1914, contained an important paper by MM. Bourget, Fabry, and Buisson of Marseille, summarizing the results of their application to the Orion nebula of the photographic interferometric methods of M. Fabry. They found var'ations 'n the radial velocity from one point to another within the nebula, differences as large as 10 km. per second at points quite close to each other being indicated by local deformations of the interference rings. They also detected graat collective movements, the northeastern region receding, and the southwestern region approaching, relatively to the mean velocity at the trapezium, with velocities of about 5 km. per second. It seemed of interest to repeat these determinations independently by the standard spectrographic method, and toward the close of the winter observations were begun at Yerkes Observatory with the Bruce spectrograph, arranged with a dispersion of one prism. The radial velocity was inferred from the displacements of the hydrogen lines 0 and 7 and the lines of nebulium at X 5007 and 4959. At the position of the western star of the trapezium, No. 619 in Bond's catalogue of stars in the nebula, the radial velocity of the nebula was found from measures .of eight plates (taken occasionally during the past eleven years) to be + 15.6 * 0.5 km. per second (recession). This is the mean of independent measures of each plate by the writer and Mr. C. A. Maney, and it agrees almost exactly with the value of + 15.8 km. found by the observers at Marseille for the region of the trapezium. For several other positions around the trapezium, and not over 2' from it; we obtained values ranging from +6 to +17 km. The probable error for the velocity at one point, from the mean of measures by the two observers of a single plate, should be about == 1.5 km., so that the reality of the difference may be regarded as fully confirmed. Exposures of from two to three hours were required at some of the positions, so that the accumulation of plates was slow, and additional observations will be required when the 'open season' for Orion returns. We must accordingly alter our conceptions of the nebula as an enormous mass of quiescent gas, and regard it as seething with local whirlpools besides perhaps having a considerable motion of rotation as a whole. 416
CAR T-cell Therapy: A New Era in Cancer Immunotherapy

Androulla N Miliotou,Lefkothea C Papadopoulou,Androulla N. Miliotou,Lefkothea C. Papadopoulou

DOI: https://doi.org/10.2174/1389201019666180418095526

2018-05-31

Current Pharmaceutical Biotechnology

Abstract:BACKGROUND: Cancer is one of the leading causes of death worldwide. Over the years, a number of conventional cytotoxic approaches for neoplastic diseases has been developed. However, due to their limited effectiveness in accordance with the heterogeneity of cancer cells, there is a constant search for therapeutic approaches with improved outcome, such as immunotherapy that utilizes and enhances the normal capacity of the patient's immune system.METHODS: Chimeric Antigen Receptor (CAR) T-cell therapy involves genetic modification of patient's autologous T-cells to express a CAR specific for a tumor antigen, following by ex vivo cell expansion and re-infusion back to the patient. CARs are fusion proteins of a selected single-chain fragment variable from a specific monoclonal antibody and one or more T-cell receptor intracellular signaling domains. This T-cell genetic modification may occur either via viral-based gene transfer methods or nonviral methods, such as DNA-based transposons, CRISPR/Cas9 technology or direct transfer of in vitro transcribed-mRNA by electroporation.RESULTS: Clinical trials have shown very promising results in end-stage patients with a full recovery of up to 92% in Acute Lymphocytic Leukemia. Despite such results in hematological cancers, the effective translation of CAR T-cell therapy to solid tumors and the corresponding clinical experience is limited due to therapeutic barriers, like CAR T-cell expansion, persistence, trafficking, and fate within tumors.CONCLUSION: In this review, the basic design of CARs, the main genetic modification strategies, the safety matters as well as the initial clinical experience with CAR T-cells are described.

pharmacology & pharmacy,biochemistry & molecular biology
Genome Editing in Engineered T Cells for Cancer Immunotherapy

Chiara Bonini,Aude G Chapuis,Michael Hudecek,Sonia Guedan,Chiara Magnani,Waseem Qasim

DOI: https://doi.org/10.1089/hum.2023.128

Abstract:Advanced gene transfer technologies and profound immunological insights have enabled substantial increases in the efficacy of anticancer adoptive cellular therapy (ACT). In recent years, the U.S. Food and Drug Administration and European Medicines Agency have approved six engineered T cell therapeutic products, all chimeric antigen receptor-engineered T cells directed against B cell malignancies. Despite encouraging clinical results, engineered T cell therapy is still constrained by challenges, which could be addressed by genome editing. As RNA-guided Clustered Regularly Interspaced Short Palindromic Repeats technology passes its 10-year anniversary, we review emerging applications of genome editing approaches designed to (1) overcome resistance to therapy, including cancer immune evasion mechanisms; (2) avoid unwanted immune reactions related to allogeneic T cell products; (3) increase fitness, expansion capacity, persistence, and potency of engineered T cells, while preserving their safety profile; and (4) improve the ability of therapeutic cells to resist immunosuppressive signals active in the tumor microenvironment. Overall, these innovative approaches should widen the safe and effective use of ACT to larger number of patients affected by cancer.
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing

Alexander Dimitri,Friederike Herbst,Joseph A. Fraietta

DOI: https://doi.org/10.1186/s12943-022-01559-z

IF: 37.3

2022-03-18

Molecular Cancer

Abstract:Abstract Chimeric Antigen Receptor (CAR) T-cells represent a breakthrough in personalized cancer therapy. In this strategy, synthetic receptors comprised of antigen recognition, signaling, and costimulatory domains are used to reprogram T-cells to target tumor cells for destruction. Despite the success of this approach in refractory B-cell malignancies, optimal potency of CAR T-cell therapy for many other cancers, particularly solid tumors, has not been achieved. Factors such as T-cell exhaustion, lack of CAR T-cell persistence, cytokine-related toxicities, and bottlenecks in the manufacturing of autologous products have hampered the safety, effectiveness, and availability of this approach. With the ease and accessibility of CRISPR-Cas9-based gene editing, it is possible to address many of these limitations. Accordingly, current research efforts focus on precision engineering of CAR T-cells with conventional CRISPR-Cas9 systems or novel editors that can install desired genetic changes with or without introduction of a double-stranded break (DSB) into the genome. These tools and strategies can be directly applied to targeting negative regulators of T-cell function, directing therapeutic transgenes to specific genomic loci, and generating reproducibly safe and potent allogeneic universal CAR T-cell products for on-demand cancer immunotherapy. This review evaluates several of the ongoing and future directions of combining next-generation CRISPR-Cas9 gene editing with synthetic biology to optimize CAR T-cell therapy for future clinical trials toward the establishment of a new cancer treatment paradigm.

oncology,biochemistry & molecular biology
Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy

Carlos A Ramos,Gianpietro Dotti

DOI: https://doi.org/10.1517/14712598.2011.573476

2011-04-04

Expert Opinion on Biological Therapy

Abstract:INTRODUCTION: Chimeric antigen receptors (CARs) usually combine the antigen binding site of a monoclonal antibody with the signal activating machinery of a T cell, freeing antigen recognition from MHC restriction and thus breaking one of the barriers to more widespread application of cellular therapy. Similar to treatment strategies employing monoclonal antibodies, T cells expressing CARs are highly targeted, but additionally offer the potential benefits of active trafficking to tumor sites, in vivo expansion and long-term persistence. Furthermore, gene transfer allows the introduction of countermeasures to tumor immune evasion and of safety mechanisms.AREAS COVERED: The basic structure of so-called first and later generation CARs and their potential advantages over other immune therapy systems. How these molecules can be grafted into immune cells (including retroviral and non-retroviral transduction methods) and strategies to improve the in vivo persistence and function of immune cells expressing CARs. Examples of tumor-associated antigens that have been targeted in preclinical models and clinical experience with these modified cells. Safety issues surrounding CAR gene transfer into T cells and potential solutions to them.EXPERT OPINION: Because of recent advances in immunology, genetics and cell processing, CAR-modified T cells will likely play an increasing role in the cellular therapy of cancer, chronic infections and autoimmune disorders.

medicine, research & experimental,biotechnology & applied microbiology
CAR-T cell therapy: current limitations and potential strategies

Robert C. Sterner,Rosalie M. Sterner

DOI: https://doi.org/10.1038/s41408-021-00459-7

IF: 9.812

2021-04-01

Blood Cancer Journal

Abstract:Abstract Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certain subsets of B cell leukemia or lymphoma, many challenges limit the therapeutic efficacy of CAR-T cells in solid tumors and hematological malignancies. Barriers to effective CAR-T cell therapy include severe life-threatening toxicities, modest anti-tumor activity, antigen escape, restricted trafficking, and limited tumor infiltration. In addition, the host and tumor microenvironment interactions with CAR-T cells critically alter CAR-T cell function. Furthermore, a complex workforce is required to develop and implement these treatments. In order to overcome these significant challenges, innovative strategies and approaches to engineer more powerful CAR-T cells with improved anti-tumor activity and decreased toxicity are necessary. In this review, we discuss recent innovations in CAR-T cell engineering to improve clinical efficacy in both hematological malignancy and solid tumors and strategies to overcome limitations of CAR-T cell therapy in both hematological malignancy and solid tumors.

oncology,hematology
Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions

Alaa Alnefaie,Sarah Albogami,Yousif Asiri,Tanveer Ahmad,Saqer S. Alotaibi,Mohammad M. Al-Sanea,Hisham Althobaiti

DOI: https://doi.org/10.3389/fbioe.2022.797440

IF: 5.7

2022-06-22

Frontiers in Bioengineering and Biotechnology

Abstract:Adaptive immunity, orchestrated by B-cells and T-cells, plays a crucial role in protecting the body from pathogenic invaders and can be used as tools to enhance the body's defense mechanisms against cancer by genetically engineering these immune cells. Several strategies have been identified for cancer treatment and evaluated for their efficacy against other diseases such as autoimmune and infectious diseases. One of the most advanced technologies is chimeric antigen receptor (CAR) T-cell therapy, a pioneering therapy in the oncology field. Successful clinical trials have resulted in the approval of six CAR-T cell products by the Food and Drug Administration for the treatment of hematological malignancies. However, there have been various obstacles that limit the use of CAR T-cell therapy as the first line of defense mechanism against cancer. Various innovative CAR-T cell therapeutic designs have been evaluated in preclinical and clinical trial settings and have demonstrated much potential for development. Such trials testing the suitability of CARs against solid tumors and HIV are showing promising results. In addition, new solutions have been proposed to overcome the limitations of this therapy. This review provides an overview of the current knowledge regarding this novel technology, including CAR T-cell structure, different applications, limitations, and proposed solutions.

multidisciplinary sciences

Effect of goldthioglucose on long-term cultures of mouse hypothalamus.

Genetically engineered T cells for cancer immunotherapy

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance

Engineering strategies to safely drive CAR T-cells into the future

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy

Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility

Advanced strategies in improving the immunotherapeutic effect of CAR‐T cell therapy

CAR T cells: Building on the CD19 paradigm

Laboratory Studies of IS Failure as Escalating Commitment to a Failing Course of Action: Overcoming the Obstacles

CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments

CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers

Radial Velocities Within the Great Nebula of Orion.

CAR T-cell Therapy: A New Era in Cancer Immunotherapy

Genome Editing in Engineered T Cells for Cancer Immunotherapy

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing

Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy

CAR-T cell therapy: current limitations and potential strategies

Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions